Angiotech is conducting a detailed analysis that seeks to determine the root cause of the imbalance between the two study groups, and will work with its Clinical Events Committee, the DSMB, the Medicines and Healthcare products Regulatory Agency, and the U.S. Food and Drug Administration to make near term decisions about the continuation of the trials.
Note on Forward Looking Statements
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the
words "believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and constitute "forward-looking
information" within the meaning of applicable Canadian securities laws. All
such statements are made pursuant to the "safe harbor" provisions of
applicable securities legislation. Forward-looking statements may involve,
but are not limited to, comments with respect to our strategies or future
actions, our targets, expectations for our financial condition and the
results of, or outlook for, our operations, research development and
product and drug development. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the followi
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved